About
NK Cell Therapies for Cancer
Areas of Focus
Categories
Stem Cell & Cellular TherapySan Diego & Southern California
Clinical Trials (7)
View allTotal Trials
7
As Lead Sponsor
4
As Collaborator
3
Total Enrollment
289
By Phase
PHASE2: 2PHASE1: 3PHASE1/PHASE2: 2
By Status
RECRUITING: 4TERMINATED: 1WITHDRAWN: 1ACTIVE_NOT_RECRUITING: 1
Clinical Trials Pipeline7 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Today
Hover over trial bars to see details
Recent Trials
NCT06991114Lead Sponsor
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
PHASE2Recruiting
90 participants
Started: Jul 9, 2025 · Completed: Jan 31, 2029
NCT06699771Collaborator
Phase 1 to Investigate the Safety, Tolerability, and Efficacy of GCC2005 in Patients With R/R NK and T-cell Malignancies
PHASE1Recruiting
48 participants
Started: Mar 7, 2025 · Completed: Aug 31, 2027
NCT06581562Collaborator
Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.
PHASE1Recruiting
30 participants
Started: May 15, 2024 · Completed: Dec 31, 2028
NCT06265220Lead Sponsor
AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus
PHASE1Recruiting
51 participants
Started: Apr 3, 2024 · Completed: Aug 31, 2027
NCT05883449Collaborator
Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL
PHASE2Terminated
25 participants
Started: Oct 10, 2023 · Completed: Jun 13, 2025
Locations (1)
Headquarters
San Diego, CA, United States
Map
Loading map...